

Date: 18th July, 2017

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,


**Sub: Alembic Pharmaceuticals Limited receives USFDA Approval for
Olmesartan Medoxomil and Amlodipine Tablets**

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Approval for Olmesartan Medoxomil and Amlodipine Tablets. Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,
For Alembic Pharmaceuticals Limited



R. K. Baheti
Director - Finance & CFO

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

PRESS RELEASE

18th July, 2017, Vadodara, India

Alembic Pharmaceuticals receives USFDA Approval for Olmesartan Medoxomil and Amlodipine Tablets

Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Olmesartan Medoxomil and Amlodipine Tablets, 20 mg/5 mg, 40 mg/5 mg, 20 mg/10 mg, and 40 mg/10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Azor® Tablets, 20 mg/5 mg, 40 mg/5 mg, 20 mg/10 mg, and 40 mg/10 mg, of Daiichi Sankyo Inc. Olmesartan Medoxomil and Amlodipine Tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure.

Olmesartan Medoxomil and Amlodipine Tablets have an estimated market size of US\$ 312 million for twelve months ending December 2016 according to IMS.

Alembic now has a total of 61 ANDA approvals (53 final approvals and 8 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at <http://www.alembicpharmaceuticals.com/>;
(Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai	Mitanshu Shah
Phone: +91 22 - 306 11681	Phone: +91 265 - 3007630
Email: ajay.desai@alembic.co.in	Email: mitanshu.shah@alembic.co.in



ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE : ALEMBIC ROAD, VADODARA - 390 003. • TEL : (0265) 2280550, 2280880 • FAX : (0265) 2281229
website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123